BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Myelodysplastic syndromes clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for myelodysplastic syndromes: 175 (113 sponsors; 22 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 7.7, rank 83 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 54, Phase 2 61, Phase 3 31, Phase 4 2, N/A 27.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Bristol-Myers Squibb BMY8NA 4, P3 3, P4 110
Wuhan Createrna Science and Technology Co., Ltd4P3 3, P2 101
Hoffmann-La Roche3P3 301
Novartis Pharmaceuticals NVS11NA 5, P3 2, P1 2, P2 202
Alexion Pharmaceuticals, Inc.5NA 3, P3 200
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.5P3 2, P1 2, NA 140
Regeneron Pharmaceuticals REGN4P3 2, P1 1, P2 110
Takeda TAK4P3 2, P2 200
Nanjing Chia-tai Tianqing Pharmaceutical3P2 1, P3 200
Celgene2P3 200
Orca Biosystems, Inc.4P3 1, P2 1, P1 200
Taiho Oncology, Inc.4P3 1, P2 1, P1 202
Geron Corporation GERN2P3 1, P4 110
AbbVie ABBV1P3 100
Ascentage Pharma Group Inc. AAPG1P3 100
Bisirna Therapeutics (Suzhou) Co., Ltd. new entrant1P3 110
Kyntra Bio KYNB new entrant1P3 110
Otsuka Australia Pharmaceutical Pty Ltd1P3 100
Bellicum Pharmaceuticals4P1 2, P2 200
AstraZeneca AZN3P2 1, NA 200
NovelMed Therapeutics3P2 300
Ossium Health, Inc.3NA 2, P2 110
Akeso2P2 200
ARCE Therapeutics, Inc.2P2 1, NA 100
Faron Pharmaceuticals Ltd2P2 211

New-entrant sponsors: Bisirna Therapeutics (Suzhou) Co., Ltd., Kyntra Bio.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Kind Pharmaceuticals LLCNCT06304103 A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic SyndromeMyelodysplastic Syndromesrecruiting63
2026-12 est.P2Ryvu Therapeutics SANCT06987058 RVU120 Rollover StudyAdvanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndromeenrolling by invitation14

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P1/P2Aptose Biosciences Inc.NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory AcuteLeukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Brecruiting240
2026-09-08P1/P2BlueSphere Bio, IncNCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDSAML, Adult Recurrent; ALL, Recurrent, Adult; MDSterminated2
2026-08 est.P1/P2AB ScienceNCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acutrecruiting78
2026-07-14P1/P2Ossium Health, Inc.NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignAcute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; Aactive not recruiting12
2026-06 est.P1/P2Advanced BioDesignNCT05601726 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AMAcute Myeloid Leukemia, Adult; Myelodysplastic Syndromesrecruiting36

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myelodysplastic syndromes"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.